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Introduction
Immunization is one of the most beneficial and cost-effective 
methods for preventing disease,1 with an estimated 20 million pre-
vented deaths from infections worldwide over the last two decades.2 
Diseases that can be prevented by vaccines recommended for ado-
lescents include tetanus, diphtheria, pertussis, and certain types of 
meningococcal disease and human papillomavirus (HPV) infec-
tion. Tetanus and diphtheria are uncommon in the US largely 
because of successful immunization programs,3,4 but the others 
remain significant public health concerns. In the US, pertussis rates 
have increased over the last few decades with more than 10,000 
cases reported in 2007,3,5 an estimated 1,400–2,800 cases of inva-
sive meningococcal disease occur annually with a case fatality 
ratio of 10%–14%,6,7 and HPV is a common sexually transmitted 
infection8 that accounts for thousands of cancers annually.9 Since 
2005, new vaccines for these diseases have been licensed for use and 
recommended for adolescents by the US Advisory Committee on 
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Immunization Practices (ACIP), including tetanus, diphtheria and 
acellular pertussis (Tdap) vaccine (licensed for use in 2005), menin-
gococcal conjugate vaccine (MCV4; licensed for use in 2005) and 
quadrivalent HPV vaccine (licensed for use in 2006).6,10,11
For 2008, the year of our study, ACIP recommended the fol-
lowing immunization schedule for adolescents aged 11–18 years.12 
A booster dose of Tdap vaccine should be administered to adoles-
cents aged 11–12 years who completed the recommended child-
hood vaccination series for tetanus, diphtheria and pertussis and 
have not received a tetanus and diphtheria toxoids (Td) vaccine 
booster dose. Adolescents aged 13–18 years who did not receive 
Tdap while they were 11–12 years old or received only Td should 
also receive a dose of Tdap in certain cases.10 While Tdap is the 
preferred vaccine, Td can be administered in situations where 
Tdap is not available.10 One dose of MCV4 should be adminis-
tered at 11–12 years of age with catch-up vaccination for adoles-
cents aged 13–18 years who have not been previously vaccinated. 
Meningococcal polysaccharide vaccine (MPSV4) is an acceptable 
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vaccine.13 Although Healthy People 2010 did not set goals for 
HPV or meningococcal vaccination, current tetanus booster vac-
cination rates are well below the goal of 90% coverage.14
Recent research has identified correlates of HPV vaccination 
among adolescent females, including older age, having health 
insurance coverage, recent utilization of healthcare, doctor’s rec-
ommendation to get vaccinated, and their parents’ beliefs about 
the vaccine.15-19 Less is known about correlates of tetanus booster 
and meningococcal vaccination among adolescents, though NIS-
Teen data suggest uptake of these vaccines may differ by age and 
race.13 Furthermore, to our knowledge, the existing literature has 
not examined uptake of all three recommended adolescent vac-
cines, the preferred public health outcome. We aimed to charac-
terize vaccination coverage of tetanus booster, meningococcal and 
HPV vaccines among adolescent females from southeastern North 
Carolina. We examined characteristics of adolescent females, their 
parents and their households as potential correlates of vaccination.
Results
Of 1,220 eligible parents contacted, 889 (73%) completed 
baseline interviews.20 Of 873 baseline respondents eligible for 
follow-up, 650 (74%) completed follow-up interviews.21 Three 
parents prematurely ended their follow-up interviews. Thus, we 
report data obtained during follow-up interviews with parents on 
vaccination histories of 647 adolescent females aged 11–20 years 
(who were aged 10–18 years at the time of baseline interviews).
Most parents were 40 years of age or older (79%), female 
(94%), non-Hispanic white (74%) or non-Hispanic African 
American (20%), had at least some college education (81%), and 
reported a household income of $60,000 or more (56%) (Table 
1). Half lived in rural areas. The daughters’ mean age was 16 years 
old (range 11–20), and most parents indicated their daughters had 
private health insurance (82%) and had a preventive care visit in 
the last year (83%).
Few parents (17%, 111/647) reported their daughters had 
received all three recommended adolescent vaccines. However, 
most indicated their daughters had received one (42%, 273/647) 
or two (33%, 212/647) of these vaccines (Fig. 1). Most parents 
reported their daughters had received tetanus booster vaccine 
(Td or Tdap; 87%; 565/647), but fewer reported their daughters 
had received meningococcal vaccine (MCV4 or MPSV4; 36%; 
234/647) or initiated the HPV vaccine series (36%; 231/647). 
Eight percent (51/647) of parents reported their daughters had 
not received any of the three recommended adolescent vaccines.
Correlates of receiving recommended adolescent vaccines. 
In bivariate analyses, daughters who were older or had preven-
tive care visits in the last year had received a greater number of 
the three recommended adolescent vaccines (Table 2). Daughters 
whose parents had at least some college education or reported 
a household income of $60,000 or more (compared to parents 
who reported a household income of less than $60,000) had also 
received more of these vaccines.
Multivariate analyses yielded similar results. Daughters aged 
13–15 years (OR = 1.70, 95% CI: 1.09–2.64) or 16–20 years 
(OR = 2.28, 95% CI: 1.51–3.44) had received a greater number 
alternative to MCV4, though administration of MCV4 is pre-
ferred. The three-dose quadrivalent HPV vaccine regimen should 
be given routinely to all females aged 11–12 years, with catch-up 
vaccination for older females (aged 13–26 years). The bivalent 
HPV vaccine was not available in the US in 2008.
While these recommended vaccines provide substantial health 
benefits, many adolescents may never receive them. The 2008 
National Immunization Survey-Teen (NIS-Teen) found that 
28% of 13–17 year-old adolescents had not received any doses of 
tetanus booster vaccine (Tdap, Td or unknown tetanus booster 
vaccine type) since age 10, 58% had not received meningococcal 
vaccine (MCV4 or unknown meningococcal vaccine type), and 
63% of female adolescents had not received any doses of HPV 
Table 1. characteristics of parents and their daughters in the follow-up 




      11–12 106 (16)
      13–15 194 (30)
      16–20 347 (54)
Health Insurance
      None 34 (5)
      public Only 81 (13)
      private 532 (82)
Had a Preventive Care Visit in Last Year
      No 110 (17)
      Yes 537 (83)
Parent Characteristics
Age (years)
      <40 133 (21)
      40+ 514 (79)
Sex
      Female 609 (94)
      Male 38 (6)
Race
      Non-Hispanic White 479 (74)
      Non-Hispanic african american 131 (20)
      Other 37 (6)
Education Level
      High school or Less 122 (19)
      some college or More 525 (81)
Household Characteristics
Income
      <$60,000 259 (40)
      $60,000+ 361 (56)
      Not Reported 27 (4)
Urbanicity
      Rural 321 (50)
      Urban 326 (50)
www.landesbioscience.com Human Vaccines 69
vs. 64%).13 While the difference in tetanus booster vaccine uptake 
may be partly due to reliance on parental reports of daughters’ 
vaccination histories (NIS-Teen estimates are based on provider 
records), we believe it is more likely due to the recent Tdap school 
requirements in North Carolina. Beginning in August 2008, the 
state required all 6th grade students attending public schools (and 
12 year olds in non-public schools) to receive a booster dose of 
Tdap, provided it had been five or more years since their last dose 
of Td.22 North Carolina also required individuals enrolling in a 
college or university for the first time on or after July 1, 2008 to 
receive a booster dose of Tdap, provided Td or Tdap had not been 
administered within the past 10 years.22 As data collection for 
this study occurred exclusively after these requirements went into 
effect (whereas NIS-Teen was conducted both before and after), 
our results may simply reflect the effectiveness of the new Tdap 
school requirements. School requirements do not currently exist in 
North Carolina for HPV or meningococcal vaccination.22
Interestingly, the correlates of vaccination were similar across 
the four outcomes examined in our analyses. Daughters whose 
parents indicated they had preventive care visits in the last year 
were often more likely to have received recommended adolescent 
vaccines. However, while most (83%) daughters had a preventive 
care visit in the last year, relatively few of these daughters had 
received all three vaccines, suggesting missed opportunities to 
vaccinate.23 Developing and implementing a standard of care and 
structured visits for adolescents, including an adolescent immu-
nization platform,24 may decrease such missed opportunities. 
Physician vaccination reminder systems can also help increase 
vaccination levels,25,26 yet remain underused by healthcare pro-
viders.27 Furthermore, almost 20% of parents indicated their 
daughters did not have a preventive care visit within the last year, 
despite recommendations that all adolescents should have such 
of these recommended adolescent vaccines compared to daugh-
ters aged 11–12 years. Daughters who had preventive care visits 
in the last year (OR = 4.81, 95% CI: 3.14–7.34) or whose parents 
had at least some college education (OR = 1.90, 95% CI: 1.29–
2.80) had also received a greater number of these vaccines.
Correlates of tetanus booster, meningococcal and hpv vac-
cination. In multivariate analyses, tetanus booster vaccination 
was more common among daughters aged 16–20 years compared 
to those aged 11–12 years (OR = 2.00, 95% CI: 1.09–3.67) 
(Table 3). Parents were also more likely to report tetanus booster 
vaccination if their daughters had preventive care visits in the 
last year (OR = 2.94, 95% CI: 1.74–4.95) or had also received 
meningococcal vaccine (OR = 2.66, 95% CI: 1.44–4.90).
For meningococcal vaccination, daughters aged 16–20 years 
were more likely to have been vaccinated compared to those 
aged 13–15 years in multivariate analyses (OR = 1.68, 95% CI: 
1.13–2.50) (Table 3). Meningococcal vaccination was also more 
common among daughters who had received tetanus booster vac-
cine (OR = 2.85, 95% CI: 1.53–5.33) or at least one dose of HPV 
vaccine (OR = 2.29, 95% CI: 1.60–3.27).
In multivariate analyses, daughters aged 13–15 years (OR = 
2.31, 95% CI: 1.32–4.04) or 16–20 years (OR = 2.04, 95% CI: 
1.21–3.44) were more likely to have received one or more doses 
of HPV vaccine compared to those aged 11–12 years (Table 3). 
Parents were also more likely to report HPV vaccination if their 
daughters had preventive care visits in the last year (OR = 7.24, 
95% CI: 3.55–14.78), their daughters had also received meningo-
coccal vaccine (OR = 2.27, 95% CI: 1.60–3.23) or the parents had 
at least some college education (OR = 1.69, 95% CI: 1.04–2.73).
Sensitivity analyses. Few parents responded “don’t know” to 
vaccination items for tetanus booster (n = 15) and HPV (n = 9) 
vaccines, while 99 parents indicated they did not know if their 
daughters had received meningococcal vaccine. We conducted 
sensitivity analyses to explore the effect of classifying daughters 
whose parents responded “don’t know” to vaccination items as “not 
vaccinated.” When we excluded these daughters from analyses, the 
results did not meaningfully change for any of the outcomes exam-
ined (data not shown), giving us confidence in our findings.
Discussion
Despite national recommendations for HPV, tetanus booster and 
meningococcal vaccines,12 vaccination levels among adolescent 
females in these five North Carolina counties were suboptimal, 
with just 17% of parents indicating their daughters had received 
all three vaccines. To our knowledge, this represents the first 
estimate of having received all three of these recommended vac-
cines among adolescent females. The percentage of parents who 
reported their daughters had received tetanus booster vaccine was 
slightly below the Healthy People 2010 goal of 90% vaccine cov-
erage (set for adolescents aged 13–15 years),14 and meningococcal 
and HPV vaccination levels were much lower.
HPV vaccine uptake in our study was highly similar to the 2008 
NIS-Teen estimate for North Carolina (36% vs. 34%), as was 
meningococcal vaccine uptake (36% vs. 31%).13 However, tetanus 
booster vaccine uptake was noticeably higher in our study (87% 
Figure 1. adolescent vaccines received as reported by parents (n = 
647). Figure does not show 51 parents (8%) who reported their daugh-
ters had not received any of these vaccines. Tetanus booster vaccine 
includes tetanus, diphtheria and acellular pertussis (Tdap) vaccine or 
tetanus and diphtheria toxoids (Td) vaccine. Meningococcal vaccine 
includes meningococcal conjugate vaccine (McV4) or meningococcal 
polysaccharide vaccine (MpsV4).
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vaccination). Concomitant administration of adolescent vaccines 
could capitalize on the tendency of adolescents who get one vaccine 
to also get others. ACIP currently recommends administering teta-
nus booster and meningococcal vaccines during the same health-
care visit if both are indicated and available.10 ACIP also currently 
states that HPV vaccine can be administered at the same visit as 
other adolescent vaccines, because concomitant administration 
visits annually.28,29 For these adolescents, alternative vaccination 
settings, such as school-based health centers, may be an option to 
consider for increasing vaccination.30
Adolescents who received one of the recommended vaccines 
examined in this study were often more likely to have received 
other recommended adolescent vaccines examined (e.g., receipt 
of tetanus booster vaccine was correlated with meningococcal 
Table 2. correlates of receiving recommended adolescent vaccines (tetanus booster,a meningococcal,b and HpV vaccines) (n = 647)








n (%) Bivariate OR (95% CI) Multivariate OR (95% CI)
Daughter Characteristics
Age (years)
         11–12 15 (14) 49 (46) 31 (29) 11 (10) ref. ref.
         13–15 16 (8) 81 (42) 69 (36) 28 (14) 1.57 (1.01–2.45)* 1.70 (1.09–2.64)*
         16–20 20 (6) 143 (41) 112 (32) 72 (21) 1.97 (1.31–2.97)** 2.28 (1.51–3.44)**
Health Insurance
         None 4 (12) 16 (47) 9 (27) 5 (15) ref. --
         public Only 9 (11) 32 (40) 26 (32) 14 (17) 1.32 (0.62–2.80) --
         private 38 (7) 225 (42) 177 (33) 92 (17) 1.45 (0.76–2.80) --
Had a Preventive Care Visit in Last Year
         No 25 (23) 61 (56) 19 (17) 5 (5) ref. ref.
         Yes 26 (5) 212 (39) 193 (36) 106 (20) 4.97 (3.26–7.60)** 4.81 (3.14–7.34)**
Parent Characteristics
Age (years)
         <40 7 (5) 66 (50) 43 (32) 17 (13) ref. --
         40+ 44 (9) 207 (40) 169 (33) 94 (18) 1.20 (0.85–1.70) --
Sex
         Female 49 (8) 253 (42) 198 (33) 109 (18) ref. --
         Male 2 (5) 20 (53) 14 (37) 2 (5) 0.71 (0.40–1.26) --
Race
         Non-Hispanic White 37 (8) 205 (43) 152 (32) 85 (18) ref. --
         Non-Hispanic african american 11 (8) 57 (44) 45 (34) 18 (14) 0.89 (0.63–1.27) --
         Other 3 (8) 11 (30) 15 (41) 8 (22) 1.46 (0.79–2.70) --
Education Level
         High school or Less 19 (16) 57 (47) 35 (29) 11 (9) ref. ref.
         some college or More 32 (6) 216 (41) 177 (34) 100 (19) 2.10 (1.44–3.06)** 1.90 (1.29–2.80)**
Household Characteristics
Income
         <$60,000 23 (9) 117 (45) 84 (32) 35 (14) ref. ref.
         $60,000+ 25 (7) 144 (40) 122 (34) 70 (19) 1.37 (1.02–1.84)* 1.15 (0.85–1.57)
         Not Reported 3 (11) 12 (44) 6 (22) 6 (22) 1.06 (0.50–2.27) 0.85 (0.40–1.83)
Urbanicity
         Rural 25 (8) 136 (42) 108 (34) 52 (16) ref. --
         Urban 26 (8) 137 (42) 104 (32) 59 (18) 1.03 (0.78–1.37) --
Note: percents may not sum to 100% due to rounding. The multivariate ordinal logistic model did not include variables with dashes (--). HpV, human 
papillomavirus; OR, odds ratio; cI, confidence interval; ref., referent group. aTetanus, diphtheria and acellular pertussis (Tdap) vaccine or tetanus and 
diphtheria toxoids (Td) vaccine. bMeningococcal conjugate vaccine (McV4) or meningococcal polysaccharide vaccine (MpsV4). *p < 0.05, **p < 0.01.
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Table 3. correlates of receiving each recommended adolescent vaccine (n = 647)
Tetanus booster vaccinea Meningococcal vaccineb HPV vaccine
n (%)
Multivariate OR 
(95% CI) n (%)
Multivariate OR 





      11–12 85 (80) ref. 34 (32) 1.52 (0.88–2.63) 25 (24) ref.
      13–15 170 (88) 1.87 (0.96–3.62) 58 (30) ref. 75 (39) 2.31 (1.32–4.04)**
      16–20 310 (89) 2.00 (1.09–3.67)* 142 (41) 1.68 (1.13–2.50)* 131 (38) 2.04 (1.21–3.44)**
Health Insurance
      None 30 (88) -- 8 (24) -- 11 (32) --
      public Only 71 (88) -- 28 (35) -- 27 (33) --
      private 464 (87) -- 198 (37) -- 193 (36) --
Had a Preventive Care Visit in Last Year
      No 81 (74) ref. 24 (22) ref. 9 (8) ref.
      Yes 484 (90) 2.94 (1.74–4.95)** 210 (39) 1.44 (0.86–2.43) 222 (41) 7.24 (3.55–14.78)**
Received Tetanus Booster Vaccinea
      No N/a N/a 14 (17) ref. 22 (27) --
      Yes N/a N/a 220 (39) 2.85 (1.53–5.33)** 209 (37) --
Received Meningococcal Vaccineb
      No 345 (84) ref. N/a N/a 115 (28) ref.
      Yes 220 (94) 2.66 (1.44–4.90)** N/a N/a 116 (50) 2.27 (1.60–3.23)**
Received One or More Doses of HPV Vaccine
      No 356 (86) -- 118 (28) ref. N/a N/a
      Yes 209 (90) -- 116 (50) 2.29 (1.60–3.27)** N/a N/a
Parent Characteristics
Age (years)
      <40 121 (91) -- 37 (28) ref. 45 (34) --
      40+ 444 (86) -- 197 (38) 1.55 (0.98–2.45) 186 (36) --
Sex
      Female 532 (87) -- 224 (37) -- 220 (36) --
      Male 33 (87) -- 10 (26) -- 11 (29) --
Race
      Non-Hispanic White 418 (87) -- 167 (35) -- 179 (37) --
      Non-Hispanic african american 113 (86) -- 49 (37) -- 39 (30) --
      Other 34 (92) -- 18 (49) -- 13 (35) --
Education Level
      High school or Less 101 (83) -- 30 (25) ref. 29 (24) ref.
      some college or More 464 (88) -- 204 (39) 1.59 (0.99–2.56) 202 (38) 1.69 (1.04–2.73)*
Household Characteristics
Income
      <$60,000 225 (87) -- 81 (31) ref. 84 (32) --
      $60,000+ 317 (88) -- 144 (40) 1.27 (0.89–1.83) 137 (38) --
      Not Reported 23 (85) -- 9 (33) 1.03 (0.42–2.51) 10 (37) --
Urbanicity
      Rural 276 (86) -- 109 (34) -- 123 (38) --
      Urban 289 (89) -- 125 (38) -- 108 (33) --
Note: Multivariate binary logistic models did not include variables with dashes (--). HpV, human papillomavirus; OR, odds ratio; cI, confidence interval, 
ref., referent group; N/a, not applicable. aTetanus, diphtheria and acellular pertussis (Tdap) vaccine or tetanus and diphtheria toxoids (Td) vaccine. 
bMeningococcal conjugate vaccine (McV4) or meningococcal polysaccharide vaccine (MpsV4). *p < 0.05, **p < 0.01.
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females participated in a two-phase longitudinal study described 
in detail in references 20 and 21. This report includes cross-
sectional data from the follow-up interviews, since data on ado-
lescent vaccines (other than HPV vaccine) were not collected at 
baseline.
In brief, eligible counties in North Carolina, US had (1) rates 
of invasive cervical cancer substantially higher than the national 
average (i.e., incidence >10 cases/100,000 women annually from 
1993–2003 and mortality >4 cases/100,000 women annually 
from 1994–2004), (2) 20% or more African American residents 
and (3) at least 1,500 girls in the targeted age range of 10–18 
years (to allow for a minimum number of caregivers). We selected 
four rural counties (Duplin, Harnett, Sampson and Wayne) and 
a fifth urban county (Cumberland) that were geographically 
clustered in the southeastern part of the state.20
In these five counties, trained interviewers from the University 
of North Carolina Survey Research Unit contacted a probabil-
ity sample of households using random-digit-dialing (5%) or a 
non-overlapping targeted-list frame of directory-listed residential 
telephone numbers with available recent household demographic 
information (95%). They oversampled households likely to con-
tain an adolescent female in the targeted age range of 10 to 18 
years old, households likely to be African American and rural 
telephone exchanges.37
Trained personnel used computer-assisted telephone inter-
viewing equipment to interview parents, grandparents, or any 
other individual who self-identified as being responsible for the 
adolescent’s care. Interviewers attempted to speak with female 
caregivers, if possible, but interviewed male caregivers if a female 
caregiver was unavailable. Interviewers prioritized female care-
givers as they may be more knowledgeable about their daughters’ 
vaccination histories. We refer to caregivers as parents through-
out the paper. If a household contained more than one 10–18 
year-old female, interview software randomly selected one as the 
index child for the interviews. Interviewers conducted baseline 
interviews between July and October 2007 and follow-up inter-
views between October and November 2008. Parents gave verbal 
consent for the study and received $10 US for their participation 
in each survey. The Institutional Review Board at the University 
of North Carolina approved the study.
Measures. The follow-up survey collected data on uptake of 
three vaccines recommended for adolescent females:12 meningo-
coccal vaccine (MCV4 or MPSV4), tetanus booster vaccine (Tdap 
or Td) and HPV vaccine. For meningococcal vaccine, interviewers 
asked parents, “Has [name] received a meningitis shot, sometimes 
called Menactra or Menomune?” The survey assessed tetanus 
booster vaccination using the item, “Has [name] received a tet-
anus booster, also called Td or Tdap shot? Tetanus boosters are 
given every 10 years. The first booster is usually given around 11 
or 12 years of age.” For HPV vaccine, interviewers asked parents, 
“Has [name] had any shots of the HPV vaccine?” Interviewers 
also provided parents with alternate names for HPV vaccine (e.g., 
cervical cancer vaccine) at the beginning of the survey. While we 
acknowledge that three doses of HPV vaccine may be required for 
full vaccine effectiveness, we focus on HPV vaccine initiation (one 
or more doses received) in this report.
is likely to increase the number of adolescents receiving vaccines 
on schedule.11 Although parents and healthcare providers have 
expressed concerns about concomitant administration of child-
hood vaccines,31,32 most parents have allowed their children to 
receive multiple recommended vaccines during the same visit.33 
Additional research on the acceptability of concomitant adminis-
tration of adolescent vaccines to both adolescents and parents is 
needed.
Vaccination tended to be lower among younger adolescents 
in our study, even though all three vaccines have the same target 
age group of 11–12 year-old adolescents. Other studies have also 
reported lower levels of HPV and meningococcal vaccination among 
younger adolescents.15,34 While some unvaccinated 11–12 year olds 
may have not yet had the opportunity to receive all three vaccines 
but will eventually receive them, it is concerning that many may 
not. About one-third of all pertussis cases occur among 11–18 year 
olds,10 and adolescents ages 11–19 years have rates of meningococ-
cal disease higher than the general population.6 College students 
living in dormitories also face high rates of meningococcal disease.6 
About 9% of females ages 14–19 years have serologic evidence of 
infection with at least one HPV type contained in the quadrivalent 
vaccine.35 Increasing vaccination among younger adolescents may 
help reduce the prevalence of these diseases among adolescents.
Our study has several important strengths including interview-
ing a large sample of parents, examination of three recommended 
adolescent vaccines, and a good response rate. While our assess-
ment of vaccination relied on parental reports that may be subject 
to recall and social desirability error, previous research has shown 
parents can accurately recall their young children’s influenza vac-
cination status.36 Furthermore, HPV and meningococcal vaccine 
uptake was comparable to estimates from the 2008 NIS-Teen, as 
discussed previously.13 We did not collect information regarding 
which meningococcal (MPSV4 or MCV4) or tetanus booster (Tdap 
or Td) vaccines adolescents received, the timing of vaccine delivery, 
or the presence of existing conditions that may contraindicate vac-
cination. We also did not collect information on some constructs 
that may be important to vaccination behaviors or specific reasons 
why daughters had not received all vaccines. Since we interviewed 
parents from only one geographic region who had a landline tele-
phone and spoke English, the generalizability of the findings to 
populations that have different characteristics is not yet known.
Vaccination coverage among adolescent females was subop-
timal, with few parents indicating their daughters had received 
all three recommended adolescent vaccines: tetanus booster, 
meningococcal and HPV vaccines. Ensuring annual preventive 
care visits and reducing missed opportunities for vaccination at 
existing visits, perhaps by increasing concomitant administration 
of adolescent vaccines, may help increase vaccine uptake.
Materials and Methods
Study design. This study is part of the Carolina HPV 
Immunization Measurement and Evaluation (CHIME) Project 
that investigated HPV vaccine decision making in an area where 
women are at relatively high risk of invasive cervical cancer. In 
one component of the CHIME Project, caregivers of adolescent 
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additional separate outcomes using binary logistic regression. 
For each outcome, we constructed models using the previously 
described procedure, though we report only multivariate findings 
to conserve space. All analyses were unweighted and conducted 
using SPSS 17.0 (Chicago, IL) and Intercooled Stata Version 11.0 
(College Station, TX). Statistical tests were two-tailed using a 
critical alpha of 0.05.
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For each vaccine, we classified daughters as “vaccinated” 
(parents responded “yes” to the appropriate vaccination item) 
or “not vaccinated” (parents responded “no” or “don’t know” to 
the appropriate vaccination item). We also counted how many of 
these three recommended adolescent vaccines each daughter had 
received (possible range = 0–3). Interviewers collected informa-
tion on various demographic and health-related factors, which we 
examined as potential correlates of vaccination. We based urban-
icity on the census block where the parent was living.37
Data analysis. The primary outcome was a four-level ordinal 
variable indicating how many of the three vaccines (tetanus booster, 
meningococcal and at least one dose of HPV vaccine) daughters 
had received. We used ordinal logistic regression models to iden-
tify bivariate correlates. We then entered statistically significant 
bivariate correlates (p < 0.05) into a multivariate ordinal logistic 
regression model. Analyses met the assumption of proportional 
odds using methods described by Hosmer and Lemeshow.38
In subsequent analyses, we examined tetanus booster vac-
cination, meningococcal vaccination and HPV vaccination as 
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